SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress

Thu, 01 Oct 2026 08:30:00 -0400

MIAMI, Oct. 01, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced presentations at the upcoming inaugural Breakthrough T1D Clinical & Research Congress (CRC 2026) being held October 9-11, 2026 in Philadelphia, PA. Presentations will include encore Phase 1 data for SAB-142, a potentially disease-modifying, redosable immunotherapy in clinical development for the treatment of Stage 3 T1D.

“We are proud to sponsor and participate in the inaugural Breakthrough T1D

SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress

Thu, 01 Oct 2026 08:30:00 -0400

“We are proud to sponsor and participate in the inaugural Breakthrough T1D

SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress

Thu, 01 Oct 2026 08:30:00 -0400

“We are proud to sponsor and participate in the inaugural Breakthrough T1D

SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress

Thu, 01 Oct 2026 08:30:00 -0400

“We are proud to sponsor and participate in the inaugural Breakthrough T1D

SAB Biotherapeutics reports Q1 2026 results, enrollment progress

Tue, 12 May 2026 07:30:57 -0400

SAB Biotherapeutics, Inc. (NASDAQ: SABS) reported first quarter 2026 financial results and provided updates on its SAFEGUARD clinical trial for type 1 diabetes treatment SAB-142.

The company reported a net loss of $18.9 million for the quarter ended March 31, 2026, compared to a $5.2 million loss in the same period last year. Research and development expenses increased to $13.4 million from $7.7 million year-over-year, driven by investments in the SAB-142 program.

SAB Biotherapeutics maintains a cash position of $217.6 million as of March 31, 2026, following a $95 million public offering completed in March. The company stated this provides operational runway

SAB Biotherapeutics reports Q1 2026 results, enrollment progress

Tue, 12 May 2026 07:30:57 -0400

SAB Biotherapeutics, Inc. (NASDAQ: SABS) reported first quarter 2026 financial results and provided updates on its SAFEGUARD clinical trial for type 1 diabetes treatment SAB-142.

SAB Biotherapeutics maintains a cash position of $217.6 million as of March 31, 2026, following a $95 million public offering completed in March. The company stated this provides operational runway

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

Tue, 12 May 2026 07:30:00 -0400

Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027

Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes

Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities

Conference call today at 8:30 AM ET

MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

Tue, 12 May 2026 07:30:00 -0400

Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027

Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes

Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities

Conference call today at 8:30 AM ET

MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

Tue, 12 May 2026 07:30:00 -0400

Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027

Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes

Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities

Conference call today at 8:30 AM ET

MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

Tue, 12 May 2026 07:30:00 -0400

Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027

Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes

Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities

Conference call today at 8:30 AM ET

MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

Tue, 12 May 2026 07:30:00 -0400

Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027

Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes

Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities

Conference call today at 8:30 AM ET

MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

Tue, 12 May 2026 07:30:00 -0400

Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027

Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes

Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities

Conference call today at 8:30 AM ET

MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

Tue, 12 May 2026 07:30:00 -0400

Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027

Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes

Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities

Conference call today at 8:30 AM ET

MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

Tue, 12 May 2026 07:30:00 -0400

Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027

Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes

Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities

Conference call today at 8:30 AM ET

MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

Tue, 12 May 2026 07:30:00 -0400

Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027

Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes

Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities

Conference call today at 8:30 AM ET

MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

Tue, 12 May 2026 07:30:00 -0400

Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027

Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes

Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities

Conference call today at 8:30 AM ET

MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

Tue, 12 May 2026 07:30:00 -0400

Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027

Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes

Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities

Conference call today at 8:30 AM ET

MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

Tue, 12 May 2026 07:30:00 -0400

Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027

Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes

Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities

Conference call today at 8:30 AM ET

MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

Tue, 12 May 2026 07:30:00 -0400

Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027

Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes

Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities

Conference call today at 8:30 AM ET

MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

Tue, 12 May 2026 07:30:00 -0400

Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027

Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes

Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities

Conference call today at 8:30 AM ET

MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:

SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET

Tue, 05 May 2026 08:30:00 -0400

MIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that its first quarter 2026 financial results will be issued in the morning of Tuesday, May 12, 2026. Management will host a conference call and webcast at 8:30 AM ET to discuss the results and provide business updates.

To access the live conference call, participants may register here.

Conference Details:

SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET

Tue, 05 May 2026 08:30:00 -0400

To access the live conference call, participants may register here.

Conference Details:

SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET

Tue, 05 May 2026 08:30:00 -0400

To access the live conference call, participants may register here.

Conference Details:

SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET

Tue, 05 May 2026 08:30:00 -0400

To access the live conference call, participants may register here.

Conference Details:

SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET

Tue, 05 May 2026 08:30:00 -0400

To access the live conference call, participants may register here.

Conference Details:

StreetInsider.com News Articles

SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress

SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress

SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress

SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress

SAB Biotherapeutics reports Q1 2026 results, enrollment progress

SAB Biotherapeutics reports Q1 2026 results, enrollment progress

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET

SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET

SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET

SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET

SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET